In this context, canagliflozin targets AMP-activated protein kinase (AMPK) activation by complex I of the respiratory chain, inhibits lipid synthesis in mouse liver, promotes mitochondrial remodeling in adipocytes, reduces cell proliferation by impairing mitochondrial respiration in different tumor models, and counteracts renal fibrosis in chronic kidney disease by enhancing sirtuin 3 (SIRT3) expression [31–36]. Here, SIRT3 is linked to neoplasm.